Sponsors (4)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Directs the National Institute of Standards and Technology (NIST) to lead research and stakeholder work to develop and improve technical standards, best practices, and evaluation methods for biosecurity measures tied to nucleic acid synthesis screening and risk management (including risks from AI). It authorizes $5 million per year from NIST laboratory activities for fiscal years 2026–2030, requires a multi‑sector consortium to set priorities and roadmaps, and requires a report to relevant House and Senate committees within 18 months after the consortium’s first meeting. The Act also adds language to existing law explicitly listing best practices and technical standards for engineering biology and biomanufacturing (including AI risks) among NIST’s enumerated items.
The bill directs modest federal funding and creates coordinated standards-development efforts to reduce biosecurity risks and improve synthetic nucleic acid screening, while imposing modest public cost and new compliance, data-privacy, and AI-related burdens on researchers and small biotech firms.
Patients and the public will face lower biosecurity and public-health risks because federal funding supports better, more accurate nucleic acid screening tools and standards.
Scientists, researchers, and biotech firms will receive targeted research support (about $5M/year FY2026–2030) from NIST to improve nucleic acid screening tools and standards.
Universities, industry, nonprofits, and customers will gain clearer guidance and coordination through a multi-stakeholder consortium to develop consensus best practices and roadmaps.
Small biotech firms and academic labs may incur new compliance costs to meet technical standards or conformity assessments introduced by the initiative.
Researchers and commercial customers could face privacy and proprietary-data risks if centralized sequence-of-concern databases or increased data collection lack strong access controls.
Firms using AI in biomanufacturing may experience slowed adoption if the standards emphasize AI-related risk management and impose additional technical requirements.
Introduced April 28, 2025 by Andrea Salinas · Last progress April 28, 2025